RxDoctor Payments Data

Vasu Balu, MD

Internal Medicine · Westminster, MDNPI 1659504777

Payments from drug & device makers

$1,650in general payments, 2019–2025

Across 113 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$297
  • Amgen$233
  • AstraZeneca$206
  • Boehringer Ingelheim$135
  • E.r. Squibb & Sons, L.L.C.$106
  • Takeda Pharmaceuticals U.S.A., Inc.$95
  • plus $578 from 12 others

What the payments were for

  • Food & beverage$1,650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,650 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$80,438
Medicare patients
272
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide39$44,457
EliquisApixaban22$27,659
MounjaroTirzepatide19$26,939
JardianceEmpagliflozin11$18,873
JanuviaSitagliptin Phosphate15$18,279
XareltoRivaroxaban13$17,997
OzempicSemaglutide12$14,036
BrilintaTicagrelor12$5,680
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$2,136
Levothyroxine Sodium74$1,697
Atorvastatin Calcium152$1,406
Albuterol Sulfate HfaAlbuterol Sulfate33$1,152
Rosuvastatin Calcium67$1,009
Losartan Potassium70$817
Gabapentin40$808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$44$71,39658 claims
PfizerEliquis$49$27,65922 claims
Boehringer IngelheimJardiance$135$18,87311 claims
MerckJanuvia$87$18,27915 claims
Johnson & JohnsonXarelto$42$17,99713 claims
Novo NordiskOzempic$297$14,03612 claims
AstraZenecaBrilinta$206$5,68012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Westminster

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →